Product Images Regiocit

This is a table showing the blood flow rate for REGIOCIT solution at different flow rates in mL/h.*

This text provides recommendations for monitoring and adjusting anticoagulation in patients undergoing citrate anticoagulation during continuous renal replacement therapy (CRRT). It includes information on how to monitor and adjust citrate dose based on post-filter ionized calcium levels and how to detect and compensate for systemic ionized hypocalcemia. The text also recommends monitoring the total-to-ionized calcium ratio as an indirect index of citrate accumulation. Overall, the text is targeted towards healthcare professionals managing patients receiving CRRT with citrate anticoagulation.*

The text appears to be a set of instructions or guidelines related to medical treatment. It suggests steps to be taken if there are suspicions of overdose, including decreasing blood flow rate and increasing dialysate/replacement flow rate. The guidelines also suggest closely monitoring the patient's status and discontinuing citrate infusion if there is no improvement within two hours.*

This text presents a table of blood flow rates ranging from 100 to 200 mL/min and corresponding solution flow rates of REGIOCIT solution. The rates of solution flow increase or decrease at different blood flow rates and citrate doses. The text provides an example of how an increase in citrate dose by 0.5 mmol/L affects the REGIOCIT solution flow rate at a particular blood flow rate.*

This is a chart detailing changes in calcium infusion rates based on measured arterial ionized calcium levels. It provides guidelines on how to adjust the infusion rate based on the calcium levels, with various monitoring periods and recommendations to inform the physician of any changes made. The chart also includes instructions on how to administer a slow bolus of calcium chloride or gluconate if calcium levels drop too low. The initial calcium solution infusion rate is 4 mmol/h, and levels are evaluated 1 hour after commencing therapy.*

This is a description of a pharmaceutical product used for hemofiltration and regional citrate anticoagulation. The medication contains sodium chloride and sodium citrate in a concentration of 5.03 g/L and 5.29 g/L respectively. The product may also contain hydrochloric acid and water, but no other non-medicinal ingredients have been specified. This medication is administered via the extracorporeal route.*

This appears to be a table showing the component levels in mmol/L of Citrate, Sodium, and Chloride. The Citrate level is greater than 18 mmol/L while the Sodium level is 140 mmol/L and the Chloride level is 86 mmol/L.*

This appears to be a table that includes medication names along with their corresponding effect on the body. It mentions the risk of hypercalcemia when taking calcium, which can result in a reduced anticoagulation effect. It also states that the intake of vitamin D and sodium bicarbonate could increase the risk of high concentrations of certain substances in the blood. It is mentioned that in some cases, metabolic alkalosis could also lead to hypocalcaemia. This is likely a summary of the potential clinical effects of these medications, based on various types of evidence.*

This is a product label for a solution containing sodium chloride and sodium citrate. It provides the composition of the product in French (Chlorure de sodium-Citrate de sodium). The label also lists the quantities of the two components for both 5000 mL and 1000 mL solutions.*

This appears to be a report of the levels of different substances in a solution. It includes the concentration of Sodium (140mmol/L or 140mEq/L), Chloride (86mmol/L or 86mEq/L), and Citrate (18mmol/L or 54mEq/L). Additionally, the estimated osmolarity of the solution is 244 mOsm/L, and the pH is approximately 7.4.*

A solution of Sodium Chloride and Sodium Citrate is described in two languages, French and English. The solution is non-pyrogenic and used for anticoagulation during Continuous Renal Replacement Therapy. The composition of the solution includes Sodium Chloride, Sodium Citrate, and Hydrochloric Acid for pH adjustment, and is meant for extracorporeal use only. The solution has a pH of 7.4 and is pre-diluted. The product comes in a single-use solution bag and should only be used if the bag is intact and there are no visible particles. Dosing instructions are available in the packaging insert, and storage should be at 4-20°C without exposure to excessive heat. The product should not be used with natural rubber latex.*

The text is a list of components and their quantities for a solution. The solution contains Sodium chloride, Sodium citrate, Hydrochloric acid (pH adjuster), Water for Injection, and Chiorure Citrate. The table shows the quantity of each component per 1000mL or 5000mL of the solution.*

This text provides information on what to do in case of a suspected drug overdose, which is to contact your regional poison control centre for management.*

This is a description of a solution for extracorporeal use only, containing sodium chloride and sodium citrate. It is non-pyrogenic and should not be administered through direct intravenous infusion. The solution is not safe for use with natural blood. The product comes in a 5000 mL package and its composition is also provided. The solution should be stored between 4°C and 30°C and should not be exposed to excessive heat or frozen. The manufacturer, Baxter Corporation, provides a customer service contact for any questions or concerns.*